| How Array Got Its Groove Back Ohad Hammer submits:Array’s (ARRY) recent licensing deal with Novartis (NVS) is another evidence of pharma’s appetite for new oncology compounds, especially for targeted agents. Facing a patent cliff and dwindling internal pipelines, pharmaceutical companies are willing to pay a generous price for promising early stage compounds.This is why companies with broad platform technologies that can feed the industry with new compounds represent an attractive investment opportunity. These companies include (in alphabetical order) Arqule (ARQL), Array, Exelixis (EXEL), Immunogen (IMGN), Micromet (MITI) and Seattle Genetics (SGEN).Complete Story » seekingalpha.com |
MannKind Bear Analysts Strike Again KLLJ Investments submits: The nice thing about being a bad Wall Street analyst, is nobody knows how bad you are until your call goes terribly wrong. Often times, there are more forces at work to bring about a poor recommendation. I’m not saying that is necessarily the case here, but you have to wonder. My local weatherman is usually more accurate about my 10-day forecast than a majority of the Wall Street analysts out there. What is unfortunate is how much an upgrade or downgrade can impact the short term trend of a security, especially when those recommendations are based on little, if any research. Many investors look to the Analysts as being experts in the firms they cover and those analysts who fail to live up to their duty as an independent auditor of sorts for those companies do a disservice to their profession.Complete Story » seekingalpha.com |
Glaxo to Book $2.4 Billion Charge GlaxoSmithKline said it will record a charge of $2.4 billion to cover the cost of settling lawsuits involving the diabetes drug Avandia and the antidepressant Paxil, and a U.S. investigation of a Glaxo factory in Puerto Rico. online.wsj.com |
New Clue in Heart Disease Researchers have discovered a mysterious protein in cells of people as they age and are examining its role in heart disease. online.wsj.com |
Why People Can't Make Decisions Researchers have been investigating how people's view of the world affects their lives, and how they might be able to make better decisions. online.wsj.com |